<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37512801</PMID><DateRevised><Year>2023</Year><Month>08</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-2607</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>22</Day></PubDate></JournalIssue><Title>Microorganisms</Title><ISOAbbreviation>Microorganisms</ISOAbbreviation></Journal><ArticleTitle>Humoral Immunity of Unvaccinated COVID-19 Recovered vs. Na&#xef;ve BNT162b2 Vaccinated Individuals: A Prospective Longitudinal Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1628</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/microorganisms11071628</ELocationID><Abstract><AbstractText>To study the differences in the immune response to SARS-CoV-2 infection compared to the response to vaccination, we characterized the humoral immune kinetics of these situations. In this prospective longitudinal study, we followed unvaccinated COVID-19-recovered individuals (<i>n</i> = 130) and na&#xef;ve, two-dose BNT162b2-vaccinated individuals (<i>n</i> = 372) who were age- and BMI-matched for six months during the first pandemic year. Anti-RBD-IgG, neutralizing antibodies (NAbs), and avidity were assessed monthly. For recovered patients, data on symptoms and the severity of the disease were collected. Anti-RBD-IgG and NAbs titers at peak were higher after vaccination vs. after infection, but the decline was steeper (peak log IgG: 3.08 vs. 1.81, peak log NAbs: 5.93 vs. 5.04, slopes: -0.54 vs. -0.26). Peak anti-RBD-IgG and NAbs were higher in recovered individuals with BMI &gt; 30 and in older individuals compared to individuals with BMI &lt; 30, younger population. Of the recovered, 42 (36%) experienced long-COVID symptoms. Avidity was initially higher in vaccinated individuals compared with recovered individuals, though with time, it increased in recovered individuals but not among vaccinated individuals. Here, we show that while the initial antibody titers, neutralization, and avidity are lower in SARS-CoV-2-recovered individuals, they persist for a longer duration. These results suggest differential protection against COVID-19 in recovered-unvaccinated vs. na&#xef;ve-vaccinated individuals.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Joseph</LastName><ForeName>Gili</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-2568-9751</Identifier><AffiliationInfo><Affiliation>The Sheba Pandemic Preparedness Research Institute (SPRI), and Infection Prevention &amp; Control Unit, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Carmit</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Sheba Pandemic Preparedness Research Institute (SPRI), and Infection Prevention &amp; Control Unit, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubin</LastName><ForeName>Carmit</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Gertner Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murad</LastName><ForeName>Havi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Gertner Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Indenbaum</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Central Virology Laboratory, Public Health Services, Ministry of Health, Tel-Hashomer, Ramat Gan 52621, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asraf</LastName><ForeName>Keren</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The Dworman Automated-Mega Laboratory, Sheba Medical Center, Tel-Hashomer, Ramat Gan 52621, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiss-Ottolenghi</LastName><ForeName>Yael</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Sheba Pandemic Preparedness Research Institute (SPRI), and Infection Prevention &amp; Control Unit, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Segal-Lieberman</LastName><ForeName>Gabriella</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Endocrinology, Diabetes and Metabolism, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler School of Medicine, Tel-Aviv University, Tel Aviv 69978, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kreiss</LastName><ForeName>Yitshak</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>General Management, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lustig</LastName><ForeName>Yaniv</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Central Virology Laboratory, Public Health Services, Ministry of Health, Tel-Hashomer, Ramat Gan 52621, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler School of Medicine, Tel-Aviv University, Tel Aviv 69978, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Regev-Yochay</LastName><ForeName>Gili</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-7163-4607</Identifier><AffiliationInfo><Affiliation>The Sheba Pandemic Preparedness Research Institute (SPRI), and Infection Prevention &amp; Control Unit, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler School of Medicine, Tel-Aviv University, Tel Aviv 69978, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Microorganisms</MedlineTA><NlmUniqueID>101625893</NlmUniqueID><ISSNLinking>2076-2607</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BNT162b2 vaccine</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">antibodies</Keyword><Keyword MajorTopicYN="N">humoral</Keyword><Keyword MajorTopicYN="N">immunity</Keyword><Keyword MajorTopicYN="N">immunoglobulin G</Keyword><Keyword MajorTopicYN="N">infection</Keyword><Keyword MajorTopicYN="N">neutralizing</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>29</Day><Hour>11</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>29</Day><Hour>11</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>29</Day><Hour>1</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37512801</ArticleId><ArticleId IdType="pmc">PMC10384358</ArticleId><ArticleId IdType="doi">10.3390/microorganisms11071628</ArticleId><ArticleId IdType="pii">microorganisms11071628</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO Coronavirus (COVID-19) Dashboard.  [(accessed on 1 March 2023)].  Available online:  https://covid19.who.int/</Citation></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., P&#xe9;rez Marc G., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N. Engl. J. Med. 2020;383:2603&#x2013;2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall V.J., Foulkes S., Saei A., Andrews N., Oguti B., Charlett A., Wellington E., Stowe J., Gillson N., Atti A., et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): A prospective, multicentre, cohort study. Lancet. 2021;397:1725&#x2013;1735. doi: 10.1016/S0140-6736(21)00790-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00790-X</ArticleId><ArticleId IdType="pmc">PMC8064668</ArticleId><ArticleId IdType="pubmed">33901423</ArticleId></ArticleIdList></Reference><Reference><Citation>Modenese A., Paduano S., Bargellini A., Bellucci R., Marchetti S., Bruno F., Grazioli P., Vivoli R., Gobba F. Neutralizing Anti-SARS-CoV-2 Antibody Titer and Reported Adverse Effects, in a Sample of Italian Nursing Home Personnel after Two Doses of the BNT162b2 Vaccine Administered Four Weeks Apart. Vaccines. 2021;9:652. doi: 10.3390/vaccines9060652.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9060652</ArticleId><ArticleId IdType="pmc">PMC8232293</ArticleId><ArticleId IdType="pubmed">34203652</ArticleId></ArticleIdList></Reference><Reference><Citation>Favresse J., Bayart J.-L., Mullier F., Dogn&#xe9; J.-M., Closset M., Douxfils J. Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2) Clin. Microbiol. Infect. 2021;27:1351.e5&#x2013;1351.e7. doi: 10.1016/j.cmi.2021.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.05.004</ArticleId><ArticleId IdType="pmc">PMC8106520</ArticleId><ArticleId IdType="pubmed">33975007</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin E.G., Lustig Y., Cohen C., Fluss R., Indenbaum V., Amit S., Doolman R., Asraf K., Mendelson E., Ziv A., et al. Waning Immune Humoral Response to BNT162b2 COVID-19 Vaccine over 6 Months. N. Engl. J. Med. 2021;385:e84. doi: 10.1056/NEJMoa2114583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2114583</ArticleId><ArticleId IdType="pmc">PMC8522797</ArticleId><ArticleId IdType="pubmed">34614326</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler S.E., Shurin G.V., Yost M., Anderson A., Pinto L., Wells A., Shurin M.R. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects. Microbiol. Spectr. 2021;9:e0034121. doi: 10.1128/Spectrum.00341-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/Spectrum.00341-21</ArticleId><ArticleId IdType="pmc">PMC8552678</ArticleId><ArticleId IdType="pubmed">34346750</ArticleId></ArticleIdList></Reference><Reference><Citation>Pegu A., O&#x2019;Connell S.E., Schmidt S.D., O&#x2019;Dell S., Talana C.A., Lai L., Albert J., Anderson E., Bennett H., Corbett K.S., et al. Durability of mRNA-1273 vaccine&#x2013;induced antibodies against SARS-CoV-2 variants. Science. 2021;373:1372&#x2013;1377. doi: 10.1126/science.abj4176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abj4176</ArticleId><ArticleId IdType="pmc">PMC8691522</ArticleId><ArticleId IdType="pubmed">34385356</ArticleId></ArticleIdList></Reference><Reference><Citation>Falsey A.R., Frenck R.W., Walsh E.E., Kitchin N., Absalon J., Gurtman A., Lockhart S., Bailey R., Swanson K.A., Xu X., et al. SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. N. Engl. J. Med. 2021;385:1627&#x2013;1629. doi: 10.1056/nejmc2113468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmc2113468</ArticleId><ArticleId IdType="pmc">PMC8461567</ArticleId><ArticleId IdType="pubmed">34525276</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordstr&#xf6;m P., Ballin M., Nordstr&#xf6;m A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: A retrospective, total population cohort study in Sweden. Lancet Infect. Dis. 2022;22:781&#x2013;790. doi: 10.1016/S1473-3099(22)00143-8. Erratum in Lancet Infect. Dis. 2022, 22, e159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00143-8</ArticleId><ArticleId IdType="pmc">PMC8971363</ArticleId><ArticleId IdType="pubmed">35366962</ArticleId></ArticleIdList></Reference><Reference><Citation>Modenese A., Paduano S., Bellucci R., Marchetti S., Bruno F., Grazioli P., Vivoli R., Gobba F., Bargellini A. Investigation of Possible Factors Influencing the Neutralizing Anti-SARS-CoV-2 Antibody Titer after Six Months from the Second Vaccination Dose in a Sample of Italian Nursing Home Personnel. Antibodies. 2022;11:59. doi: 10.3390/antib11030059.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antib11030059</ArticleId><ArticleId IdType="pmc">PMC9495803</ArticleId><ArticleId IdType="pubmed">36134955</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergwerk M., Gonen T., Lustig Y., Amit S., Lipsitch M., Cohen C., Mandelboim M., Levin E.G., Rubin C., Indenbaum V., et al. COVID-19 Breakthrough Infections in Vaccinated Health Care Workers. N. Engl. J. Med. 2021;385:1474&#x2013;1484. doi: 10.1056/NEJMoa2109072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2109072</ArticleId><ArticleId IdType="pmc">PMC8362591</ArticleId><ArticleId IdType="pubmed">34320281</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustig Y., Sapir E., Regev-Yochay G., Cohen C., Fluss R., Olmer L., Indenbaum V., Mandelboim M., Doolman R., Amit S., et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: A prospective, single-centre, longitudinal cohort study in health-care workers. Lancet Respir. Med. 2021;9:999&#x2013;1009. doi: 10.1016/s2213-2600(21)00220-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2213-2600(21)00220-4</ArticleId><ArticleId IdType="pmc">PMC8253545</ArticleId><ArticleId IdType="pubmed">34224675</ArticleId></ArticleIdList></Reference><Reference><Citation>Saur&#xe9; D., O&#x2019;Ryan M., Torres J.P., Zuniga M., Santelices E., Basso L.J. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: A sentinel surveillance study. Lancet Infect. Dis. 2022;22:56&#x2013;63. doi: 10.1016/S1473-3099(21)00479-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00479-5</ArticleId><ArticleId IdType="pmc">PMC8428469</ArticleId><ArticleId IdType="pubmed">34509185</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu Jabal K., Ben-Amram H., Beiruti K., Batheesh Y., Sussan C., Zarka S., Edelstein M. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: Real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Eurosurveillance. 2021;26:2100096. doi: 10.2807/1560-7917.ES.2021.26.6.2100096.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2021.26.6.2100096</ArticleId><ArticleId IdType="pmc">PMC7879501</ArticleId><ArticleId IdType="pubmed">33573712</ArticleId></ArticleIdList></Reference><Reference><Citation>Costagliola G., Spada E., Consolini R. Age-related differences in the immune response could contribute to determine the spectrum of severity of COVID-19. Immun. Inflamm. Dis. 2021;9:331&#x2013;339. doi: 10.1002/iid3.404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.404</ArticleId><ArticleId IdType="pmc">PMC8014746</ArticleId><ArticleId IdType="pubmed">33566457</ArticleId></ArticleIdList></Reference><Reference><Citation>Albashir A.A.D. The potential impacts of obesity on COVID-19. Clin. Med. 2020;20:e109&#x2013;e113. doi: 10.7861/clinmed.2020-0239.</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmed.2020-0239</ArticleId><ArticleId IdType="pmc">PMC7385759</ArticleId><ArticleId IdType="pubmed">32571783</ArticleId></ArticleIdList></Reference><Reference><Citation>Palaiodimos L., Kokkinidis D.G., Li W., Karamanis D., Ognibene J., Arora S., Southern W.N., Mantzoros C.S. Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism. 2020;108:154262. doi: 10.1016/j.metabol.2020.154262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2020.154262</ArticleId><ArticleId IdType="pmc">PMC7228874</ArticleId><ArticleId IdType="pubmed">32422233</ArticleId></ArticleIdList></Reference><Reference><Citation>Soeroto A.Y., Soetedjo N.N., Purwiga A., Santoso P., Kulsum I.D., Suryadinata H., Ferdian F. Effect of increased BMI and obesity on the outcome of COVID-19 adult patients: A systematic review and meta-analysis. Diabetes Metab. Syndr. 2020;14:1897&#x2013;1904. doi: 10.1016/j.dsx.2020.09.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2020.09.029</ArticleId><ArticleId IdType="pmc">PMC7521380</ArticleId><ArticleId IdType="pubmed">33007661</ArticleId></ArticleIdList></Reference><Reference><Citation>Soffer S., Glicksberg B.S., Zimlichman E., Efros O., Levin M.A., Freeman R., Reich D.L., Klang E. The association between obesity and peak antibody titer response in COVID-19 infection. Obesity. 2021;29:1547&#x2013;1553. doi: 10.1002/oby.23208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/oby.23208</ArticleId><ArticleId IdType="pmc">PMC8242567</ArticleId><ArticleId IdType="pubmed">33945220</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasireddy D., Vanaparthy R., Mohan G., Malayala S.V., Atluri P. Review of COVID-19 Variants and COVID-19 Vaccine Efficacy: What the Clinician Should Know? J. Clin. Med. Res. 2021;13:317&#x2013;325. doi: 10.14740/jocmr4518. Erratum in J. Clin. Med. Res. 2021, 13, 412.</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/jocmr4518</ArticleId><ArticleId IdType="pmc">PMC8256910</ArticleId><ArticleId IdType="pubmed">34267839</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., Tang P., Hasan M.R., AlMukdad S., Yassine H.M., Benslimane F.M., Al Khatib H.A., Coyle P., Ayoub H.H., Al Kanaani Z., et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N. Engl. J. Med. 2021;385:e83. doi: 10.1056/NEJMoa2114114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2114114</ArticleId><ArticleId IdType="pmc">PMC8522799</ArticleId><ArticleId IdType="pubmed">34614327</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitale J., Mumoli N., Clerici P., De Paschale M., Evangelista I., Cei M., Mazzone A. Assessment of SARS-CoV-2 Reinfection 1 Year After Primary Infection in a Population in Lombardy, Italy. JAMA Intern. Med. 2021;181:1407&#x2013;1408. doi: 10.1001/jamainternmed.2021.2959.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2021.2959</ArticleId><ArticleId IdType="pmc">PMC8164145</ArticleId><ArticleId IdType="pubmed">34048531</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  2020 Clinical Management of COVID-19: Interim Guidance, 27 May 2020.  [(accessed on 1 March 2023)].  Available online:  https://apps.who.int/iris/handle/10665/332196.</Citation></Reference><Reference><Citation>Lustig Y., Gonen T., Meltzer L., Gilboa M., Indenbaum V., Cohen C., Amit S., Jaber H., Doolman R., Asraf K., et al. Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose. Nat. Immunol. 2022;23:940&#x2013;946. doi: 10.1038/s41590-022-01212-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-022-01212-3</ArticleId><ArticleId IdType="pubmed">35534723</ArticleId></ArticleIdList></Reference><Reference><Citation>Shenai M.B., Rahme R., Noorchashm H. Equivalency of Protection from Natural Immunity in COVID-19 Recovered Versus Fully Vaccinated Persons: A Systematic Review and Pooled Analysis. Cureus. 2021;13:e19102. doi: 10.7759/cureus.19102.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.19102</ArticleId><ArticleId IdType="pmc">PMC8627252</ArticleId><ArticleId IdType="pubmed">34868754</ArticleId></ArticleIdList></Reference><Reference><Citation>Trougakos I.P., Terpos E., Zirou C., Sklirou A.D., Apostolakou F., Gumeni S., Charitaki I., Papanagnou E.-D., Bagratuni T., Liacos C.-I., et al. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and na&#xef;ve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. BMC Med. 2021;19:208. doi: 10.1186/s12916-021-02090-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-02090-6</ArticleId><ArticleId IdType="pmc">PMC8380479</ArticleId><ArticleId IdType="pubmed">34420521</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarkowski M., de Jager W., Schiuma M., Covizzi A., Lai A., Gabrieli A., Corbellino M., Bergna A., Della Ventura C., Galli M., et al. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity against Viral Variants, According to BNT162b2-Vaccination and Infection History. Front. Immunol. 2021;12:793191. doi: 10.3389/fimmu.2021.793191.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.793191</ArticleId><ArticleId IdType="pmc">PMC8718396</ArticleId><ArticleId IdType="pubmed">34975897</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzi L., Focosi D., Dentali F., Baj A., Maggi F. Anti-SARS-CoV-2 RBD IgG responses in convalescent versus na&#xef;ve BNT162b2 vaccine recipients. Vaccine. 2021;39:2489&#x2013;2490. doi: 10.1016/j.vaccine.2021.03.086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.03.086</ArticleId><ArticleId IdType="pmc">PMC8009041</ArticleId><ArticleId IdType="pubmed">33824042</ArticleId></ArticleIdList></Reference><Reference><Citation>Lozano-Rodr&#xed;guez R., Valent&#xed;n-Quiroga J., Avenda&#xf1;o-Ortiz J., Mart&#xed;n-Quir&#xf3;s A., Pascual-Iglesias A., Terr&#xf3;n-Arcos V., Montalb&#xe1;n-Hern&#xe1;ndez K., Casalvilla-Due&#xf1;as J.C., Berg&#xf3;n-Guti&#xe9;rrez M., Alcam&#xed; J., et al. Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19. Cell Rep. 2021;38:110235. doi: 10.1016/j.celrep.2021.110235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.110235</ArticleId><ArticleId IdType="pmc">PMC8687760</ArticleId><ArticleId IdType="pubmed">34986327</ArticleId></ArticleIdList></Reference><Reference><Citation>Struck F., Schreiner P., Staschik E., Wochinz-Richter K., Schulz S., Soutschek E., Motz M., Bauer G. Vaccination versus infection with SARS-CoV-2: Establishment of a high avidity IgG response versus incomplete avidity maturation. J. Med. Virol. 2021;93:6765&#x2013;6777. doi: 10.1002/jmv.27270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27270</ArticleId><ArticleId IdType="pmc">PMC8427118</ArticleId><ArticleId IdType="pubmed">34387884</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilboa M., Regev-Yochay G., Mandelboim M., Indenbaum V., Asraf K., Fluss R., Amit S., Mendelson E., Doolman R., Afek A., et al. Durability of Immune Response After COVID-19 Booster Vaccination and Association with COVID-19 Omicron Infection. JAMA Netw. Open. 2022;5:e2231778. doi: 10.1001/jamanetworkopen.2022.31778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.31778</ArticleId><ArticleId IdType="pmc">PMC9478782</ArticleId><ArticleId IdType="pubmed">36107426</ArticleId></ArticleIdList></Reference><Reference><Citation>Altarawneh H.N., Chemaitelly H., Ayoub H.H., Tang P., Hasan M.R., Yassine H.M., Al-Khatib H.A., Smatti M.K., Coyle P., Al-Kanaani Z., et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. N. Engl. J. Med. 2022;387:21&#x2013;34. doi: 10.1056/NEJMoa2203965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2203965</ArticleId><ArticleId IdType="pmc">PMC9258753</ArticleId><ArticleId IdType="pubmed">35704396</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruenjaiman V., Sodsai P., Kueanjinda P., Bunrasmee W., Klinchanhom S., Reantragoon R., Tunvirachaisakul C., Manothummetha K., Mejun N., Liengswangwong K., et al. Impact of SARS-CoV-2 infection on the profiles and responses of innate immune cells after recovery. Pt 1J. Microbiol. Immunol. Infect. 2022;55:993&#x2013;1004. doi: 10.1016/j.jmii.2022.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2022.09.001</ArticleId><ArticleId IdType="pmc">PMC9519362</ArticleId><ArticleId IdType="pubmed">36220753</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorrentino L., Fracella M., Frasca F., D&#x2019;auria A., Santinelli L., Maddaloni L., Bugani G., Bitossi C., Gentile M., Ceccarelli G., et al. Alterations in the Expression of IFN Lambda, IFN Gamma and Toll-like Receptors in Severe COVID-19 Patients. Microorganisms. 2023;11:689. doi: 10.3390/microorganisms11030689.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms11030689</ArticleId><ArticleId IdType="pmc">PMC10058642</ArticleId><ArticleId IdType="pubmed">36985262</ArticleId></ArticleIdList></Reference><Reference><Citation>Li K., Huang B., Wu M., Zhong A., Li L., Cai Y., Wang Z., Wu L., Zhu M., Li J., et al. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. Nat. Commun. 2020;11:6044. doi: 10.1038/s41467-020-19943-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19943-y</ArticleId><ArticleId IdType="pmc">PMC7699636</ArticleId><ArticleId IdType="pubmed">33247152</ArticleId></ArticleIdList></Reference><Reference><Citation>Osborn O., Olefsky J.M. The cellular and signaling networks linking the immune system and metabolism in disease. Nat. Med. 2012;18:363&#x2013;374. doi: 10.1038/nm.2627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2627</ArticleId><ArticleId IdType="pubmed">22395709</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotamisligil G.S. Inflammation and metabolic disorders. Nature. 2006;444:860&#x2013;867. doi: 10.1038/nature05485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05485</ArticleId><ArticleId IdType="pubmed">17167474</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixit V.D. Adipose-immune interactions during obesity and caloric restriction: Reciprocal mechanisms regulating immunity and health span. J. Leukoc. Biol. 2008;84:882&#x2013;892. doi: 10.1189/jlb.0108028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.0108028</ArticleId><ArticleId IdType="pmc">PMC2638733</ArticleId><ArticleId IdType="pubmed">18579754</ArticleId></ArticleIdList></Reference><Reference><Citation>Fantuzzi G. Adipose tissue, adipokines, and inflammation. J. Allergy Clin. Immunol. 2005;115:911&#x2013;919. doi: 10.1016/j.jaci.2005.02.023. quiz 920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2005.02.023</ArticleId><ArticleId IdType="pubmed">15867843</ArticleId></ArticleIdList></Reference><Reference><Citation>Papathanassoglou E., El-Haschimi K., Li X.C., Matarese G., Strom T., Mantzoros C. Leptin Receptor Expression and Signaling in Lymphocytes: Kinetics during Lymphocyte Activation, Role in Lymphocyte Survival, and Response to High Fat Diet in Mice. J. Immunol. 2006;176:7745&#x2013;7752. doi: 10.4049/jimmunol.176.12.7745.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.176.12.7745</ArticleId><ArticleId IdType="pubmed">16751422</ArticleId></ArticleIdList></Reference><Reference><Citation>Menges D., Ballouz T., Anagnostopoulos A., Aschmann H.E., Domenghino A., Fehr J.S., Puhan M.A. Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study. PLoS ONE. 2021;16:e0254523. doi: 10.1371/journal.pone.0254523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0254523</ArticleId><ArticleId IdType="pmc">PMC8274847</ArticleId><ArticleId IdType="pubmed">34252157</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H., Raza S., Nowell J., Young M., Edison P. Long Covid&#x2014;Mechanisms, Risk Factors, and Management. BMJ. 2021;374:n1648. doi: 10.1136/bmj.n1648. Erratum in BMJ 2021, 374, n1944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Yelin D., Margalit I., Nehme M., Bordas-Mart&#xed;nez J., Pistelli F., Yahav D., Guessous I., Dur&#xe0;-Miralles X., Carrozzi L., Shapira-Lichter I., et al. Patterns of Long COVID Symptoms: A Multi-Center Cross Sectional Study. J. Clin. Med. 2022;11:898. doi: 10.3390/jcm11040898.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11040898</ArticleId><ArticleId IdType="pmc">PMC8875229</ArticleId><ArticleId IdType="pubmed">35207171</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal S., Barnett J., Brill S.E., Brown J.S., Denneny E.K., Hare S.S., Heightman M., Hillman T.E., Jacob J., Jarvis H.C., et al. &#x2018;Long-COVID&#x2019;: A cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2021;76:396&#x2013;398. doi: 10.1136/thoraxjnl-2020-215818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-215818</ArticleId><ArticleId IdType="pmc">PMC7615158</ArticleId><ArticleId IdType="pubmed">33172844</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>